Study guide

15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment

Certified Burn Registered Nurse CBRN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Foundations of Burn Care

1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones

2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response

2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria

3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics

4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)

4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy

5 Chapter 5: Airway Management & Inhalation Injury Management

5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)

6 Chapter 6: Acute Multisystem Assessment & Critical Care Management

6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection

7 Chapter 7: Hypermetabolism & Nutritional Support

7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

8 Chapter 8: Pain Management in Burn Care

8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction

9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings

10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances

11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure

11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management

12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy

12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion

13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries

13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy

14 Chapter 14: Special Burn Populations & Cutaneous Syndromes

14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries

15 Chapter 15: Rehabilitation, Scar Management & Reconstruction

15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management

16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage

16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response

15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment

Key Takeaways Explain This Topic AI

Burn wounds requiring >14-21 days to achieve complete re-epithelialization exhibit an exponential rise in hypertrophic scar (HTS) development, reaching an incidence of 70% to >80%.

The molecular pathophysiology of HTS is governed by prolonged inflammatory cytokine signaling (particularly TGF-β1 and TGF-β2), excessive differentiation of fibroblasts into α-SMA-positive myofibroblasts, failure of myofibroblast apoptosis, and dense nodular whorls of disorganized type III collagen.

Hypertrophic scars are raised, erythematous, and rigid, remaining confined within the original wound boundaries and undergoing partial maturation over 1-2 years, whereas keloids actively invade surrounding uninjured dermis, lack spontaneous regression, and exhibit strong genetic/familial predisposition.

The Vancouver Scar Scale (VSS) is the gold standard clinical tool assessing four domains: Vascularity (0-3), Pigmentation (0-3), Pliability (0-5), and Height/Thickness (0-3), yielding a composite severity score from 0 (normal) to 13 (maximum scar severity).

The Patient and Observer Scar Assessment Scale (POSAS) complements the VSS by incorporating subjective patient symptoms (pruritus, neuropathic pain, stiffness) alongside observer parameters.

Last updated: August 2026

15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment

Core Knowledge: Hypertrophic scarring (HTS) is the most prevalent, distressing, and functionally debilitating long-term complication of deep thermal injury. Occurring in over 70 % – 80 % 70\%\text{--}80\% 70% – 80% of burn wounds that require longer than 21 days 21\text{ days} 21 days to heal, HTS represents a state of pathological fibroproliferation driven by persistent chronic inflammation, sustained transforming growth factor-beta (TGF- β \beta β ) signaling, failure of myofibroblast apoptosis, and excessive deposition of disorganized extracellular matrix (ECM). Accurate, objective clinical monitoring using validated tools like the Vancouver Scar Scale (VSS) is essential for guiding compression, topical therapies, and surgical reconstruction.

1. Pathophysiology and Kinetics of Hypertrophic Scar Formation

Normal cutaneous wound healing progresses through three overlapping phases: inflammation, proliferation (granulation and re-epithelialization), and remodeling. In hypertrophic scarring, the inflammatory and proliferative phases fail to terminate, creating an ongoing loop of excessive matrix synthesis and contraction. TIME TO HEALING VS. HYPERTROPHIC SCAR RISK

  • ┌───────────────────────┬────────────────────────────────────────────────┐
  • │ Time to Complete │ Incidence & Severity of Hypertrophic Scarring │
  • │ Re-epithelialization │ │
  • ├───────────────────────┼────────────────────────────────────────────────┤
  • │ < 14 Days │ Minimal Risk (<10%–15%); minimal dermal damage;│
  • │ (Superficial partial) │ Normal parallel collagen remodeling. │
  • ├───────────────────────┼────────────────────────────────────────────────┤
  • │ 14 to 21 Days │ Moderate Risk (30%–35%); transitional zone; │
  • │ (Mid-dermal partial) │ Prophylactic scar management recommended. │
  • ├───────────────────────┼────────────────────────────────────────────────┤
  • │ > 21 Days │ High to Severe Risk (70%–85%+); profound │
  • │ (Deep partial / full) │ chronic inflammation; aggressive HTS standard. │
  • └───────────────────────┴────────────────────────────────────────────────┘

Molecular Drivers of Hypertrophic Scarring:

Prolonged TGF- β \beta β Signaling: Transforming Growth Factor-beta isoforms play distinct roles. TGF- β 1 \beta_1 β 1 ​ and TGF- β 2 \beta_2 β 2 ​ are potent pro-fibrotic cytokines that drive fibroblast proliferation, induce myofibroblast differentiation, and stimulate massive collagen synthesis while suppressing matrix metalloproteinases (MMPs). In contrast, TGF- β 3 \beta_3 β 3 ​ promotes scarless fetal healing and matrix organization.

Inflammatory Mediators: Sustained local infiltration of mast cells (releasing histamine and promoting pruritus), macrophages, and T-lymphocytes continuously secretes platelet-derived growth factor (PDGF), connective tissue growth factor (CTGF), and interleukin-6 ( I L − 6 IL-6 I L − 6 ), maintaining a perpetual proliferative state.

Angiogenesis and Microvascular Hyperemia: Endothelial hyperactivity and vascular endothelial growth factor (VEGF) overexpression produce abundant, irregular microvessels, giving active hypertrophic scars their characteristic intense purple-red erythema.

2. Cellular Mechanisms: The Myofibroblast and Collagen Disorganization

The myofibroblast is the key cellular effector in hypertrophic scar pathology. Originating from resident dermal fibroblasts and circulating pericytes under the influence of mechanical tension and TGF- β 1 \beta_1 β 1 ​ , myofibroblasts express large intracellular bundles of alpha-smooth muscle actin ( α \alpha α -SMA) . NORMAL DERMIS VS. HYPERTROPHIC SCAR

  • ┌────────────────────────────────────────┬────────────────────────────────────────┐
  • │ NORMAL DERMAL ARCHITECTURE │ HYPERTROPHIC BURN SCAR ARCHITECTURE │
  • ├────────────────────────────────────────┼────────────────────────────────────────┤
  • │ • Collagen Ratio: 4:1 (Type I : III) │ • Collagen Ratio: Altered (High Type III)│
  • │ • Fiber Arrangement: Relaxed, parallel │ • Fiber Arrangement: Dense, nodular, │
  • │ 'basketweave' orientation │ swirling whorls & tight bundles │
  • │ • Cellularity: Low; quiescent fibrocytes│ • Cellularity: Extreme; active myofibro-│
  • │ • Microvasculature: Organized capillaries│ blasts resisting apoptosis │
  • │ • Mechanical Property: Supple, elastic │ • Microvasculature: Hypervascular, leaky│
  • │ │ • Mechanical Property: Rigid, unyielding│
  • └────────────────────────────────────────┴────────────────────────────────────────┘

In physiological wound healing, myofibroblasts undergo programmed cell death ( apoptosis ) once wound closure is achieved. In hypertrophic scarring, myofibroblast apoptosis is pathologically blocked, causing persistent cellular contraction and continuous, excessive secretion of disorganized collagen whorls that create rigid, raised scar nodules.

3. Differentiating Hypertrophic Scars from Keloids

Although both represent fibroproliferative disorders of wound healing, hypertrophic scars and keloids possess distinct clinical, histological, and genetic characteristics that dictate different therapeutic approaches.

Diagnostic Feature Hypertrophic Scar (HTS) Keloid

Boundaries Confined strictly within the borders of the original burn wound or surgical incision. Invades into surrounding normal skin , extending far beyond original wound margins.

Onset Timeline Emerges rapidly within 4 to 8 weeks post-injury; peaks around 6 months. Emerges late, often months to years after minor cutaneous trauma or spontaneously.

Natural History Undergoes gradual maturation and regression over 12 to 24 months (softens, flattens, pales). Does not regress spontaneously ; exhibits continuous, progressive outgrowths over years.

Predisposing Sites Flexor joint surfaces, anterior chest, neck, shoulders, areas of high mechanical skin tension. Earlobes, deltoid, pre-sternum, upper back; less dependent on physical tension lines.

Genetic Background Occurs across all races; equal male/female; driven primarily by wound depth and healing delay ( > 21 days >21\text{ days} > 21 days ). Strong familial and ethnic predilection (predominantly individuals with darker skin pigmentation; Fitzpatrick types IV–VI).

Histology Collagen arranged in discrete nodular whorls ; contains active myofibroblasts with α \alpha α -SMA. Large, thick, hyalinized acelluar collagen bundles ('keloidal collagen') ; lacks distinct nodules.

Response to Excision Low recurrence after excision if combined with tension relief, grafting, and pressure therapy ( < 20 % <20\% < 20% ). Extremely high recurrence rate ( > 50 % – 80 % >50\%\text{--}80\% > 50% – 80% ) when surgically excised alone.

4. Objective Scar Assessment: The Vancouver Scar Scale (VSS)

The Vancouver Scar Scale (VSS) (originally introduced by Sullivan in 1990) is the internationally recognized gold standard clinical tool for quantitative, longitudinal assessment of burn scar severity. VANCOUVER SCAR SCALE (VSS) SCORING MATRIX

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ TOTAL SCORE RANGE: 0 (Normal Skin) to 13 (Maximum Scar Severity) │
  • ├──────────────┬───────┬─────────────────────────────────────────────────┤
  • │ Parameter │ Score │ Clinical Description & Diagnostic Criteria │
  • ├──────────────┼───────┼─────────────────────────────────────────────────┤
  • │ VASCULARITY │ 0 │ Normal: Color resembles remainder of body │
  • │ │ 1 │ Pink: Slight increase in microvascular flow │
  • │ │ 2 │ Red: High vascularity, prominent capillary loop │
  • │ │ 3 │ Purple: Extreme vascularity, congestive stasis │
  • ├──────────────┼───────┼─────────────────────────────────────────────────┤
  • │ PIGMENTATION │ 0 │ Normal: Color matches surrounding native skin │
  • │ │ 1 │ Hypopigmentation: Loss of melanin pigment │
  • │ │ 2 │ Mixed Pigmentation: Mottled hyper/hypo regions │
  • │ │ 3 │ Hyperpigmentation: Excessive dark melanin deposit│
  • ├──────────────┼───────┼─────────────────────────────────────────────────┤
  • │ PLIABILITY │ 0 │ Normal: Normal cutaneous elasticity and recoil │
  • │ │ 1 │ Supple: Flexible with minimal resistance │
  • │ │ 2 │ Yielding: Gives way under moderate pressure │
  • │ │ 3 │ Firm: Solid, unyielding, resistant to movement │
  • │ │ 4 │ Ropes / Banding: Thick fibrous cords blanching │
  • │ │ 5 │ Contracture: Permanent flexion/extension deficit│
  • ├──────────────┼───────┼─────────────────────────────────────────────────┤
  • │ HEIGHT / │ 0 │ Normal / Flat: Flush with adjacent normal skin │
  • │ THICKNESS │ 1 │ < 2 mm: Mild elevation │
  • │ │ 2 │ 2 mm to 5 mm: Moderate thickness │
  • │ │ 3 │ > 5 mm: Severe hypertrophy / massive protrusion │
  • └──────────────┴───────┴─────────────────────────────────────────────────┘

Clinical Application and VSS Tracking:

Serial Measurements: The burn nurse or therapist performs VSS ratings at regular intervals (e.g., monthly during compression garment wear) to objectively quantify scar maturation.

Tracking Remodeling: As a hypertrophic scar matures, the VSS score systematically declines. Vascularity shifts from purple (3) or red (2) to pink (1) and eventually normal (0) as capillary density regresses. Pliability improves from firm (3) to supple (1), and height flattens from > 5 mm >5\text{ mm} > 5 mm (3) to flat (0).

5. Comprehensive Scar Evaluation Tools: POSAS & Modern Metrics

While the VSS provides an objective observer rating, it does not assess subjective patient symptoms. The Patient and Observer Scar Assessment Scale (POSAS) addresses this limitation by incorporating two distinct scales:

Observer Scale: Rates vascularity, pigmentation, thickness, relief, pliability, and surface area (each scored 1 to 10).

Patient Scale: Evaluates the survivor's subjective experience, scoring pain , pruritus (itching) , color difference, stiffness, thickness, and irregularity (each scored 1 to 10). OBJECTIVE BIOENGINEERING SCAR INSTRUMENTS

  • ┌────────────────────┬───────────────────────────────────────────────────┐
  • │ Instrument │ Objective Quantitative Parameter Measured │
  • ├────────────────────┼───────────────────────────────────────────────────┤
  • │ Cutometer® │ Measures vertical skin displacement via suction to│
  • │ │ quantify true biomechanical elasticity & recoil. │
  • ├────────────────────┼───────────────────────────────────────────────────┤
  • │ Mexameter® / │ Quantifies narrow-band spectrophotometric melanin │
  • │ Minolta Chromameter│ (pigmentation) and hemoglobin (erythema/vascular).│
  • ├────────────────────┼───────────────────────────────────────────────────┤
  • │ High-Frequency │ Measures scar thickness and depth in millimeters │
  • │ Ultrasound (20MHz) │ with sub-millimeter anatomical precision. │
  • └────────────────────┴───────────────────────────────────────────────────┘